Completed PHASE2 INTERVENTIONAL NCT00215566

A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of DDP733 for IBS-c

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Multiple Doses and Dose Levels of DDP733 in Patients With Irritable Bowel Syndrome With Constipation

Sponsor: Dynogen Pharmaceuticals

Conditions Irritable Bowel Syndrome Irritable Bowel Syndrome With Constipation

Interventions DDP733

Updated 6 times since 2017 Last updated: May 25, 2007 Started: Sep 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Irritable Bowel Syndrome and Irritable Bowel Syndrome With Constipation, this trial is completed. The trial is conducted by Dynogen Pharmaceuticals and has accumulated 6 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dynogen Pharmaceuticals

Data source: Dynogen Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Edmonton, Canada , Guelph, Canada , Halifax, Canada , Hamilton, Canada , Kingston, Canada , London, Canada , Ottawa, Canada , Québec, Canada , Sarnia, Canada , Toronto, Canada and 2 more locations